Canadian Cancer Trials Group Bulletins

Trial Management Group

CCTG CEC.5 (Alliance A221208) | Opportunity still exists for additional sites in Canada

The CCTG CEC.5 (Alliance A221208) clinical trial is open and accruing patients in the USA and Canada! Opportunity still exists for additional sites in Canada to participate.

Randomized Phase II Study: Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BeSt) for Radionecrosis After Radiosurgery for Brain Metastases

Radionecrosis of brain metastases post-treatment with high-dose radiation (including radiosurgery), is a problem for a significant subset of patients. These patients are typically treated with corticosteroids, which can cause substantial toxicity. There are limited alternative treatments available but early data has shown promising responses to bevacizumab. This trial aims to generate data to support the clinical use of bevacizumab for radionecrosis while investigating biomarkers that may help identify which patients are most likely to respond to this treatment. Of note, patients enrolled in this study will have access to bevacizumab (provided), either at initial randomization or, if needed, at symptomatic progression (i.e. crossover).

For researchers and centers who are considering this opportunity please visit the CCTG trial page: